Literature DB >> 11199097

Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronic obstructive pulmonary disease.

T Cawston1, S Carrere, J Catterall, R Duggleby, S Elliott, B Shingleton, A Rowan.   

Abstract

The matrix metalloproteinases (MMPs) are a unique family of metalloenzymes that, once activated, can destroy connective tissue. The active enzymes are all inhibited by tissue inhibitors of metalloproteinases (TIMPs). The relative amounts of active MMPs and TIMPs are important in determining whether tissues are broken down in disease. Although elastase is often regarded as the target enzyme in chronic obstructive pulmonary disease (COPD), both the neutrophils and macrophages in the lung contain metalloproteinases and both collagen and elastin are degraded in disease. Transgenic studies have shown that when MMP1 is over-expressed, pulmonary emphysema develops in mice, while MMP12 knockout mice do not develop pulmonary emphysema when exposed to cigarette smoke. New drugs that can specifically block active MMPs are now available. These potent inhibitors are effective in vitro and prevent the destruction of tissue in animal models. Future patient trials will test the effectiveness of these compounds in preventing tissue destruction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11199097     DOI: 10.1002/0470868678.ch13

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  8 in total

1.  Elastase/LPS-exposed mice exhibit impaired innate immune responses to bacterial challenge: role of scavenger receptor A.

Authors:  Shyamala Ganesan; Andrea N Faris; Adam T Comstock; Joanne Sonstein; Jeffrey L Curtis; Uma S Sajjan
Journal:  Am J Pathol       Date:  2011-11-08       Impact factor: 4.307

2.  Double deficiency of tetraspanins CD9 and CD81 alters cell motility and protease production of macrophages and causes chronic obstructive pulmonary disease-like phenotype in mice.

Authors:  Yoshito Takeda; Ping He; Isao Tachibana; Bo Zhou; Kenji Miyado; Hideshi Kaneko; Mayumi Suzuki; Seigo Minami; Takeo Iwasaki; Sho Goya; Takashi Kijima; Toru Kumagai; Mitsuhiro Yoshida; Tadashi Osaki; Toshihisa Komori; Eisuke Mekada; Ichiro Kawase
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

Review 3.  Expression and regulation of metalloproteinases and their inhibitors in intervertebral disc aging and degeneration.

Authors:  Nam V Vo; Robert A Hartman; Takashi Yurube; Lloydine J Jacobs; Gwendolyn A Sowa; James D Kang
Journal:  Spine J       Date:  2013-01-29       Impact factor: 4.166

4.  Sequential morphological characteristics of murine fetal liver hematopoietic microenvironment in Swiss Webster mice.

Authors:  Jackline de Paula Ayres-Silva; Pedro Paulo de Abreu Manso; Mariana Rietmann da Cunha Madeira; Marcelo Pelajo-Machado; Henrique Leonel Lenzi
Journal:  Cell Tissue Res       Date:  2011-05-04       Impact factor: 5.249

5.  An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema.

Authors:  Sandra Grumelli; David B Corry; Li-Zhen Song; Ling Song; Linda Green; Joseph Huh; Joan Hacken; Rafael Espada; Remzi Bag; Dorothy E Lewis; Farrah Kheradmand
Journal:  PLoS Med       Date:  2004-10-19       Impact factor: 11.069

6.  The expression of metalloproteinases in the lumbar disc correlates strongly with Pfirrmann MRI grades in lumbar spinal fusion patients.

Authors:  Sanjay S Aripaka; Rachid Bech-Azeddine; Louise M Jørgensen; Jens D Mikkelsen
Journal:  Brain Spine       Date:  2022-02-05

7.  Discovery of Emphysema Relevant Molecular Networks from an A/J Mouse Inhalation Study Using Reverse Engineering and Forward Simulation (REFS™).

Authors:  Yang Xiang; Ulrike Kogel; Stephan Gebel; Michael J Peck; Manuel C Peitsch; Viatcheslav R Akmaev; Julia Hoeng
Journal:  Gene Regul Syst Bio       Date:  2014-02-19

Review 8.  Recent advances in pre-clinical mouse models of COPD.

Authors:  Ross Vlahos; Steven Bozinovski
Journal:  Clin Sci (Lond)       Date:  2014-02       Impact factor: 6.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.